Guy Van den Mooter

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1996170/publications.pdf

Version: 2024-02-01

80 papers	4,230 citations	159585 30 h-index	110387 64 g-index
80 all docs	80 docs citations	80 times ranked	3724 citing authors

#	Article	IF	Citations
1	Review: physical chemistry of solid dispersions. Journal of Pharmacy and Pharmacology, 2010, 61, 1571-1586.	2.4	443
2	Manufacturing of solid dispersions of poorly water soluble drugs by spray drying: Formulation and process considerations. International Journal of Pharmaceutics, 2013, 453, 253-284.	5.2	442
3	The use of amorphous solid dispersions: A formulation strategy to overcome poor solubility and dissolution rate. Drug Discovery Today: Technologies, 2012, 9, e79-e85.	4.0	436
4	Spray drying formulation of amorphous solid dispersions. Advanced Drug Delivery Reviews, 2016, 100, 27-50.	13.7	361
5	Physical State of Poorly Water Soluble Therapeutic Molecules Loaded into SBA-15 Ordered Mesoporous Silica Carriers: A Case Study with Itraconazole and Ibuprofen. Langmuir, 2008, 24, 8651-8659.	3.5	212
6	Clinical study of solid dispersions of itraconazole prepared by hot-stage extrusion. European Journal of Pharmaceutical Sciences, 2005, 24, 179-186.	4.0	140
7	Pharmaceutical Applications of Electrospraying. Journal of Pharmaceutical Sciences, 2016, 105, 2601-2620.	3.3	139
8	Review: physical chemistry of solid dispersions. Journal of Pharmacy and Pharmacology, 2009, 61, 1571-1586.	2.4	113
9	Combined use of ordered mesoporous silica and precipitation inhibitors for improved oral absorption of the poorly soluble weak base itraconazole. European Journal of Pharmaceutics and Biopharmaceutics, 2010, 75, 354-365.	4.3	111
10	Structural and Dynamic Properties of Amorphous Solid Dispersions: The Role of Solid-State Nuclear Magnetic Resonance Spectroscopy and Relaxometry. Journal of Pharmaceutical Sciences, 2014, 103, 2635-2662.	3.3	103
11	Colon drug delivery. Expert Opinion on Drug Delivery, 2006, 3, 111-125.	5.0	100
12	The role of the carrier in the formulation of pharmaceutical solid dispersions. Part II: amorphous carriers. Expert Opinion on Drug Delivery, 2016, 13, 1681-1694.	5.0	98
13	Influence of Solvent Composition on the Miscibility and Physical Stability of Naproxen/PVP K 25 Solid Dispersions Prepared by Cosolvent Spray-Drying. Pharmaceutical Research, 2012, 29, 251-270.	3.5	84
14	Ordered mesoporous silica to enhance the bioavailability of poorly water-soluble drugs: Proof of concept in man. European Journal of Pharmaceutics and Biopharmaceutics, 2016, 108, 220-225.	4.3	81
15	Unraveling Particle Formation: From Single Droplet Drying to Spray Drying and Electrospraying. Pharmaceutics, 2020, 12, 625.	4.5	72
16	Electrospraying of polymer solutions: Study of formulation and process parameters. European Journal of Pharmaceutics and Biopharmaceutics, 2017, 119, 114-124.	4.3	69
17	Can compression induce demixing in amorphous solid dispersions? A case study of naproxenâ€“PVP K25. European Journal of Pharmaceutics and Biopharmaceutics, 2012, 81, 207-213.	4.3	62
18	Solid-state analysis of amorphous solid dispersions: Why DSC and XRPD may not be regarded as stand-alone techniques. Journal of Pharmaceutical and Biomedical Analysis, 2020, 178, 112937.	2.8	60

#	Article	IF	Citations
19	Comparison Between Hot-Melt Extrusion and Spray-Drying for Manufacturing Solid Dispersions of the Graft Copolymer of Ethylene Glycol and Vinylalcohol. Pharmaceutical Research, 2011, 28, 673-682.	3.5	56
20	Downscaling Drug Nanosuspension Production: Processing Aspects and Physicochemical Characterization. AAPS PharmSciTech, 2009, 10, 44-53.	3.3	52
21	The role of the carrier in the formulation of pharmaceutical solid dispersions. Part I: crystalline and semi-crystalline carriers. Expert Opinion on Drug Delivery, 2016, 13, 1583-1594.	5.0	46
22	Chemically identical but physically different: A comparison of spray drying, hot melt extrusion and cryo-milling for the formulation of high drug loaded amorphous solid dispersions of naproxen. European Journal of Pharmaceutics and Biopharmaceutics, 2019, 135, 1-12.	4.3	46
23	Correlation between the permeability of metoprolol tartrate through plasticized isolated ethylcellulose/hydroxypropyl methylcellulose films and drug release from reservoir pellets. European Journal of Pharmaceutics and Biopharmaceutics, 2007, 67, 485-490.	4.3	42
24	Polymorphism of Indomethacin in Semicrystalline Dispersions: Formation, Transformation, and Segregation. Molecular Pharmaceutics, 2018, 15, 1037-1051.	4.6	42
25	Effect of Compression on Non-isothermal Crystallization Behaviour of Amorphous Indomethacin. Pharmaceutical Research, 2012, 29, 2489-2498.	3.5	41
26	Relating Hydrogen-Bonding Interactions with the Phase Behavior of Naproxen/PVP K 25 Solid Dispersions: Evaluation of Solution-Cast and Quench-Cooled Films. Molecular Pharmaceutics, 2012, 9, 3301-3317.	4.6	40
27	Effect of Compression on the Molecular Arrangement of Itraconazoleâ€“Soluplus Solid Dispersions: Induction of Liquid Crystals or Exacerbation of Phase Separation?. Molecular Pharmaceutics, 2016, 13, 1879-1893.	4.6	38
28	An Investigation into the Effect of Spray Drying Temperature and Atomizing Conditions on Miscibility, Physical Stability, and Performance of Naproxenâ€“PVP K 25 Solid Dispersions. Journal of Pharmaceutical Sciences, 2013, 102, 1249-1267.	3.3	36
29	Amorphous solid dispersions of darunavir: Comparison between spray drying and electrospraying. European Journal of Pharmaceutics and Biopharmaceutics, 2018, 130, 96-107.	4.3	32
30	Influence of polyethylene glycol chain length on compatibility and release characteristics of ternary solid dispersions of itraconazole in polyethylene glycol/hydroxypropylmethylcellulose 2910 E5 blends. European Journal of Pharmaceutical Sciences, 2008, 35, 203-210.	4.0	31
31	Crystallization Kinetics of Indomethacin/Polyethylene Glycol Dispersions Containing High Drug Loadings. Molecular Pharmaceutics, 2015, 12, 2493-2504.	4.6	30
32	Drugâ€“Polymer Miscibility across a Spray Dryer: A Case Study of Naproxen and Miconazole Solid Dispersions. Molecular Pharmaceutics, 2014, 11, 1094-1101.	4.6	28
33	Exploring the feasibility of the use of biopolymers as a carrier in the formulation of amorphous solid dispersions â€“ Part I: Gelatin. International Journal of Pharmaceutics, 2018, 535, 47-58.	5.2	28
34	The Influence of Spray-Drying Parameters on Phase Behavior, Drug Distribution, and In Vitro Release of Injectable Microspheres for Sustained Release. Journal of Pharmaceutical Sciences, 2015, 104, 1451-1460.	3.3	27
35	Formulating monoclonal antibodies as powders for reconstitution at high concentration using spray drying: Models and pitfalls. European Journal of Pharmaceutics and Biopharmaceutics, 2018, 127, 407-422.	4.3	27
36	A study of the aggregation of cyclodextrins: Determination of the critical aggregation concentration, size of aggregates and thermodynamics using isodesmic and K2â€“K models. International Journal of Pharmaceutics, 2017, 521, 318-326.	5.2	25

#	Article	IF	Citations
37	Comparative study of the potential of poly(2-ethyl-2-oxazoline) as carrier in the formulation of amorphous solid dispersions of poorly soluble drugs. European Journal of Pharmaceutics and Biopharmaceutics, 2019, 144, 79-90.	4.3	25
38	Formulating monoclonal antibodies as powders for reconstitution at high concentration using spray-drying: Trehalose/amino acid combinations as reconstitution time reducing and stability improving formulations. European Journal of Pharmaceutics and Biopharmaceutics, 2020, 156, 131-142.	4.3	25
39	One-step production of darunavir solid dispersion nanoparticles coated with enteric polymers using electrospraying. Journal of Pharmacy and Pharmacology, 2016, 68, 625-633.	2.4	22
40	Nanoscale Surface Characterization and Miscibility Study of a Spray-Dried Injectable Polymeric Matrix Consisting of Poly(lactic-co-glycolic acid) and Polyvinylpyrrolidone. Journal of Pharmaceutical Sciences, 2012, 101, 3473-3485.	3.3	20
41	Encapsulating darunavir nanocrystals within Eudragit L100 using coaxial electrospraying. European Journal of Pharmaceutics and Biopharmaceutics, 2017, 113, 50-59.	4.3	20
42	Spectroscopic Investigation of the Formation and Disruption of Hydrogen Bonds in Pharmaceutical Semicrystalline Dispersions. Molecular Pharmaceutics, 2017, 14, 1726-1741.	4.6	19
43	Preparation of Amorphous Solid Dispersions by Cryomilling: Chemical and Physical Concerns Related to Active Pharmaceutical Ingredients and Carriers. Molecular Pharmaceutics, 2020, 17, 1001-1013.	4.6	17
44	Controlling the Release of Indomethacin from Glass Solutions Layered with a Rate Controlling Membrane Using Fluid-Bed Processing. Part 1: Surface and Cross-Sectional Chemical Analysis. Molecular Pharmaceutics, 2017, 14, 959-973.	4.6	16
45	Ability of gelatin and BSA to stabilize the supersaturated state of poorly soluble drugs. European Journal of Pharmaceutics and Biopharmaceutics, 2018, 131, 211-223.	4.3	14
46	Myth or Truth: The Glass Forming Ability Class III Drugs Will Always Form Single-Phase Homogenous Amorphous Solid Dispersion Formulations. Pharmaceutics, 2019, 11, 529.	4.5	14
47	Gastro-resistant encapsulation of amorphous solid dispersions containing darunavir by coaxial electrospraying. International Journal of Pharmaceutics, 2020, 574, 118885.	5.2	13
48	Advancing predictions of protein stability in the solid state. Physical Chemistry Chemical Physics, 2020, 22, 17247-17254.	2.8	13
49	Microstructure of Pharmaceutical Semicrystalline Dispersions: The Significance of Polymer Conformation. Molecular Pharmaceutics, 2018, 15, 629-641.	4.6	12
50	Size Analysis of Small Particles in Wet Dispersions by Laser Diffractometry: A Guidance to Quality Data. Journal of Pharmaceutical Sciences, 2019, 108, 1905-1914.	3.3	12
51	Combination of (M)DSC and Surface Analysis to Study the Phase Behaviour and Drug Distribution of Ternary Solid Dispersions. Pharmaceutical Research, 2015, 32, 1407-1416.	3.5	11
52	Development of enteric-coated fixed dose combinations of amorphous solid dispersions of ezetimibe and lovastatin: Investigation of formulation and process parameters. International Journal of Pharmaceutics, 2017, 520, 49-58.	5.2	11
53	Influence of formulation composition and process on the characteristics and in vitro release from PLGA-based sustained release injectables. European Journal of Pharmaceutics and Biopharmaceutics, 2015, 90, 22-29.	4.3	10
54	EudragitÂ® RL as a stabilizer for supersaturation and a substrate for nanocrystal formation. European Journal of Pharmaceutics and Biopharmaceutics, 2017, 114, 250-262.	4.3	10

#	Article	IF	Citations
55	TEMPO-Oxidized Cellulose Beads as Potential pH-Responsive Carriers for Site-Specific Drug Delivery in the Gastrointestinal Tract. Molecules, 2021, 26, 1030.	3.8	10
56	Immiscibility of Chemically Alike Amorphous Polymers: Phase Separation of Poly(2-ethyl-2-oxazoline) and Poly(2-n-propyl-2-oxazoline). Macromolecules, 2020, 53, 7590-7600.	4.8	9
57	Porous soluble dialdehyde cellulose beads: A new carrier for the formulation of poorly water-soluble drugs. International Journal of Pharmaceutics, 2022, 615, 121491.	5.2	9
58	The Peculiar Behavior of the Glass Transition Temperature of Amorphous Drug-Polymer Films Coated on Inert Sugar Spheres. Journal of Pharmaceutical Sciences, 2015, 104, 1759-1766.	3.3	8
59	Controlling the Release of Indomethacin from Glass Solutions Layered with a Rate Controlling Membrane Using Fluid-Bed Processing. Part 2: The Influence of Formulation Parameters on Drug Release. Molecular Pharmaceutics, 2017, 14, 974-983.	4.6	8
60	Complex amorphous solid dispersions based on poly(2-hydroxyethyl methacrylate): Study of drug release from a hydrophilic insoluble polymeric carrier in the presence and absence of a porosity increasing agent. International Journal of Pharmaceutics, 2019, 566, 77-88.	5.2	8
61	Drug-carrier binding and enzymatic carrier digestion in amorphous solid dispersions containing proteins as carrier. International Journal of Pharmaceutics, 2019, 563, 358-372.	5.2	8
62	Fixed dose combinations for cardiovascular treatment via coaxial electrospraying: Coated amorphous solid dispersion particles. International Journal of Pharmaceutics, 2020, 577, 118949.	5.2	8
63	The influence of crushing amorphous solid dispersion dosage forms on the in-vitro dissolution kinetics. International Journal of Pharmaceutics, 2020, 573, 118884.	5.2	8
64	Complementarity of mDSC, DMA, and DRS Techniques in the Study of T_g and Sub-T_g Transitions in Amorphous Solids: PVPVA, Indomethacin, and Amorphous Solid Dispersions Based on Indomethacin/PVPVA. Molecular Pharmaceutics, 2022, 19, 2299-2315.	4.6	8
65	Tracking solid state dynamics in spray-dried protein powders at infrared and terahertz frequencies. European Journal of Pharmaceutics and Biopharmaceutics, 2019, 144, 244-251.	4.3	7
66	Feasibility of electrospraying fully aqueous bovine serum albumin solutions. European Journal of Pharmaceutics and Biopharmaceutics, 2020, 147, 102-110.	4.3	7
67	The underestimated contribution of the solvent to the phase behavior of highly drug loaded amorphous solid dispersions. International Journal of Pharmaceutics, 2021, 609, 121201.	5.2	7
68	Co-administration of darunavir and a new pharmacokinetic booster: Formulation strategies and evaluation in dogs. European Journal of Pharmaceutical Sciences, 2010, 41, 193-200.	4.0	6
69	Unravelling the Miscibility of Poly(2-oxazoline)s: A Novel Polymer Class for the Formulation of Amorphous Solid Dispersions. Molecules, 2020, 25, 3587.	3.8	6
70	Mechanodegradation of Polymers: A Limiting Factor of Mechanochemical Activation in the Production of Amorphous Solid Dispersions by Cryomilling. Molecular Pharmaceutics, 2020, 17, 2987-2999.	4.6	6
71	Solvatomorphism in Miconazole: The Role of Weak Câ€“HÂ·Â·Â·Cl Hydrogen Bonds and Câ€“ClÂ·Â·Â·Clâ€“C Halogen Interactions in Similarities and Differences in the Crystal Packing. Crystal Growth and Design, 2022, 22, 2703-2724.	3.0	5
72	Electrospraying the Triblock Copolymer SEBS: The Effect of Solvent System and the Embedding of Quantum Dots. Macromolecular Materials and Engineering, 2020, 305, 1900658.	3.6	4

#	Article	IF	Citations
73	Development of a Surface Coating Technique with Predictive Value for Bead Coating in the Manufacturing of Amorphous Solid Dispersions. Pharmaceutics, 2020, 12, 878.	4.5	4
74	Solvent influence on manufacturability, phase behavior and morphology of amorphous solid dispersions prepared via bead coating. European Journal of Pharmaceutics and Biopharmaceutics, 2021, 167, 175-188.	4.3	4
75	Investigating the Potential of Ethyl Cellulose and a Porosity-Increasing Agent as a Carrier System for the Formulation of Amorphous Solid Dispersions. Molecular Pharmaceutics, 2022, 19, 2712-2724.	4.6	4
76	Shedding a light on the physical stability of suspensions micronised with intensified vibratory milling; A trend observed with decreasing particle size as a function of time. International Journal of Pharmaceutics, 2021, 603, 120687.	5.2	3
77	Gaining Insight into the Role of the Solvent during Spray Drying of Amorphous Solid Dispersions by Studying Evaporation Kinetics. Molecular Pharmaceutics, 2022, 19, 1604-1618.	4.6	3
78	The Value of Bead Coating in the Manufacturing of Amorphous Solid Dispersions: A Comparative Evaluation with Spray Drying. Pharmaceutics, 2022, 14, 613.	4.5	2
79	Exploration of the heat generation within the intensified vibratory mill. International Journal of Pharmaceutics, 2020, 587, 119644.	5.2	1
80	Picking up good vibrations: Exploration of the intensified vibratory mill via a modern design of experiments. International Journal of Pharmaceutics, 2021, 598, 120367.	5.2	0